CN112741154A - Formula liquid milk for premature infants and preparation method thereof - Google Patents
Formula liquid milk for premature infants and preparation method thereof Download PDFInfo
- Publication number
- CN112741154A CN112741154A CN201911044599.8A CN201911044599A CN112741154A CN 112741154 A CN112741154 A CN 112741154A CN 201911044599 A CN201911044599 A CN 201911044599A CN 112741154 A CN112741154 A CN 112741154A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- mass concentration
- milk
- liquid milk
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 83
- 210000004080 milk Anatomy 0.000 title claims abstract description 83
- 239000008267 milk Substances 0.000 title claims abstract description 80
- 239000007788 liquid Substances 0.000 title claims abstract description 79
- 230000002028 premature Effects 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 235000013350 formula milk Nutrition 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 33
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 29
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 29
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 25
- 239000008158 vegetable oil Substances 0.000 claims abstract description 25
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 18
- 239000008103 glucose Substances 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 235000013373 food additive Nutrition 0.000 claims abstract description 17
- 239000002778 food additive Substances 0.000 claims abstract description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 17
- 239000011707 mineral Substances 0.000 claims abstract description 17
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 16
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 16
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 16
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 16
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 235000021119 whey protein Nutrition 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 15
- 239000008101 lactose Substances 0.000 claims abstract description 15
- 229960003080 taurine Drugs 0.000 claims abstract description 14
- 239000005862 Whey Substances 0.000 claims abstract description 13
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 12
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract 2
- 235000020247 cow milk Nutrition 0.000 claims abstract 2
- 239000004615 ingredient Substances 0.000 claims description 18
- 235000020185 raw untreated milk Nutrition 0.000 claims description 18
- -1 compound vitamin Chemical class 0.000 claims description 17
- 230000001954 sterilising effect Effects 0.000 claims description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052802 copper Inorganic materials 0.000 claims description 10
- 239000010949 copper Substances 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229910052742 iron Inorganic materials 0.000 claims description 7
- 229940083466 soybean lecithin Drugs 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- 229930003448 Vitamin K Natural products 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 6
- 239000003240 coconut oil Substances 0.000 claims description 6
- 235000019864 coconut oil Nutrition 0.000 claims description 6
- 235000005687 corn oil Nutrition 0.000 claims description 6
- 239000002285 corn oil Substances 0.000 claims description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- 229940055726 pantothenic acid Drugs 0.000 claims description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 229960003495 thiamine Drugs 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims description 6
- 239000011691 vitamin B1 Substances 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 235000019166 vitamin D Nutrition 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 235000019168 vitamin K Nutrition 0.000 claims description 6
- 239000011712 vitamin K Substances 0.000 claims description 6
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 229940046008 vitamin d Drugs 0.000 claims description 6
- 229940046010 vitamin k Drugs 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 235000019486 Sunflower oil Nutrition 0.000 claims 2
- 239000000828 canola oil Substances 0.000 claims 2
- 235000019519 canola oil Nutrition 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- 239000002600 sunflower oil Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 29
- 235000020601 preterm formula Nutrition 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000000047 product Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000001953 sensory effect Effects 0.000 description 9
- 235000019621 digestibility Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 235000019620 fat digestibility Nutrition 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000009189 diving Effects 0.000 description 5
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 4
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 4
- 235000019484 Rapeseed oil Nutrition 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000020238 sunflower seed Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dairy Products (AREA)
Abstract
一种早产儿配方液态乳及其制备方法，属于早产儿配方食品加工技术领域。为了解决传统早产儿配方奶粉冲调麻烦、外出携带不方便、浓度不均一以及存在卫生安全隐患的问题，本发明提供了一种早产儿配方液态乳及其制备方法，所述液态乳由生牛乳，脱脂乳，复配植物油，乳清蛋白粉，脱盐乳清粉，乳糖，葡萄糖聚合物，复配维生素，复配矿物质，核苷酸，牛磺酸，乳铁蛋白，动物双歧杆菌Bb‑12和食品添加剂制成。本发明所述的早产儿配方液态乳无需冲调，相对于传统的早产儿配方奶粉食用便利，浓度更加均一，更加卫生安全。A formula liquid milk for premature infants and a preparation method thereof belong to the technical field of formula food processing for premature infants. In order to solve the problems that traditional formula milk powder for premature infants is troublesome to prepare, inconvenient to carry when going out, the concentration is not uniform, and there are potential health and safety hazards, the present invention provides a formula liquid milk for premature infants and a preparation method thereof. The liquid milk is made of raw cow milk. , skim milk, compound vegetable oil, whey protein powder, demineralized whey powder, lactose, glucose polymer, compound vitamins, compound minerals, nucleotides, taurine, lactoferrin, Bifidobacterium animalis Bb ‑12 and food additives. Compared with the traditional formula milk powder for premature infants, the formula liquid milk for premature infants of the present invention does not need to be reconstituted, is convenient to eat, has a more uniform concentration, and is more hygienic and safe.
Description
Technical Field
The invention relates to formula liquid milk for premature infants and a preparation method thereof, belonging to the technical field of formula food processing for premature infants.
Background
Preterm infants are neonates with gestational age less than 37 weeks, i.e., neonates with gestational age less than 259 days. The premature infant born in each year in China is about 100 ten thousand, the premature infant needs high energy supply to make up for the low birth weight, the premature infant can grow at a growth speed exceeding that of a full-term infant after birth, the sucking and swallowing reflex of the premature infant is not perfect, the gastrointestinal secretion and the digestive function are weak, and the digestive function disorder and the nutritional disorder are easily caused. Meanwhile, premature babies cannot fully absorb the nutrients in mothers, so that the growth and storage requirements cannot be met, the problems of incomplete development of tissues and organs, incomplete function and low resistance are easily caused, and the growth, development and digestive ability are poor due to the fact that nutrients required for growth cannot be timely supplemented after birth. The correct feeding of premature infants means that the premature infants need to be fed correctly to meet the requirements of growth and development because the premature infants need to be fed correctly not only to avoid dysplasia and long-term cognitive behavior caused by insufficient essential nutrients and conditional essential nutrients, but also to avoid the risk that overnutrition may increase metabolic diseases such as hypertension, hyperlipidemia, type II diabetes and the like after adults.
The infant formula liquid milk is internationally recognized as one of the most advanced infant foods at present, represents a brand new feeding concept, is highly concerned by the industry since the market, is relatively strange for most people, and is a new thing. Foreign enterprises such as the minister of Meizan, the Yapei, the love of Taimei, the cowshed and the like have own brands of infant formula liquid milk for a long time, and have been produced and sold for more than ten years, but domestic consumers have little knowledge of the brands. Currently, infant formula liquid milk is being produced and sold in many countries around the world, such as the united states, finland, etc., which are becoming new players in the infant formula market.
The infant formula liquid milk becomes a new pet in the infant formula food market, and mainly has the advantages that firstly, the infant formula liquid milk does not need to be brewed, a lot of time is saved, the infant formula liquid milk has great attraction to office workers, secondly, compared with the brewed infant formula milk powder, the concentration of the infant formula liquid milk is uniform, the infant formula liquid milk is convenient to feed and suitable for being carried outdoors, and most importantly, the infant formula liquid milk is safe and sanitary, and is more beneficial to healthy growth of infants.
At present, infant formula liquid milk in domestic and foreign markets is mainly divided into three segments (the segment 1 is 0-6 months old, the segment 2 is 6-12 months old, and the segment 3 is 12-36 months old), and formula liquid milk products for premature infants are not provided, so that the research and development of the formula liquid milk for premature infants are vital, theoretical basis is provided for production, and technical guidance is provided for production.
Disclosure of Invention
The invention provides a premature formula liquid milk and a preparation method thereof, and aims to solve the problems that the traditional premature formula milk powder is troublesome to prepare, inconvenient to carry when people go out, non-uniform in concentration and hidden health and safety hazards exist. The formula liquid milk for the premature infant is prepared from the following raw materials in percentage by volume based on the prepared liquid milk: the mass concentration of raw milk is 62-115g/L, the mass concentration of skim milk is 62-65g/L, the mass concentration of compound vegetable oil is 11.6-28.8g/L, the mass concentration of whey protein powder is 6.5-7.5g/L, the mass concentration of desalted whey powder is 91-100g/L, the mass concentration of lactose is 22.5-58.5g/L, the mass concentration of glucose polymer is 2.5-6.5g/L, the mass concentration of compound vitamin is 0.25-0.5g/L, the mass concentration of compound mineral is 0.2-0.5g/L, the mass concentration of nucleotide is 0.05-0.09g/L, the mass concentration of taurine is 0.4-0.5mg/L, the mass concentration of lactoferrin is 0.05-0.13g/L, the mass concentration of animal bifidobacterium Bb-12 is 1800 white matter/L, the mass concentration of the food additive is 0.95-1.02 g/L.
Preferably, the compound vegetable oil is composed of soybean oil, corn oil, low erucic acid rapeseed oil, coconut oil and high oleic acid sunflower seed oil, and the mass ratio of the soybean oil, the corn oil, the low erucic acid rapeseed oil, the coconut oil and the high oleic acid sunflower seed oil is 5:37:23:19: 15.
Preferably, the compound vitamin is composed of vitamin A, vitamin D, vitamin K, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, pantothenic acid, vitamin C, biotin and choline, and the mass ratio of the vitamin A, the vitamin D, the vitamin K, the vitamin E, the vitamin B1, the vitamin B2, the vitamin B6, the vitamin B12, the nicotinamide, the folic acid, the pantothenic acid, the vitamin C, the biotin and the choline is 31:0.57:0.9:370:12.6:18.7:9.6:0.017:102.5:3.55:69:1630: 3429.
Preferably, the compound mineral is composed of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium, and the mass ratio of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium is 3841:8213:5.71:859:114:111:0.43:7430:4290:1.86:82130: 0.17.
Preferably, based on the volume of the prepared liquid milk, the mass concentration of the soybean lecithin in the food additive is 0.5-0.52g/L, the mass concentration of the monoglyceride and diglyceride fatty acid ester is 0.45-0.5g/L, the mass concentration of calcium carbonate is 1-1.5mg/L, and the mass concentration of calcium bicarbonate is 0.05-0.1 mg/L.
Preferably, the ratio of the total mass of whey protein to the total mass of casein in raw milk and skim milk is (5-6): 1.
the preparation method of the formula liquid milk for the premature infant comprises the following steps:
(1) filtering raw milk;
(2) mixing and dissolving the raw milk, the skim milk, the whey protein powder, the desalted whey powder, the lactose, the glucose polymer, the compound mineral, the nucleotide, the taurine, the lactoferrin, the bifidobacterium animalis Bb-12, the calcium carbonate and the calcium monohydrogen phosphate in the food additive and water after the filtration in the step (1) to obtain a water-soluble ingredient solution;
(3) adding the compound vitamins, soybean lecithin and mono-diglycerol fatty acid ester in the food additive into the compound vegetable oil, and mixing and dissolving the mixture to obtain a fat-soluble ingredient solution;
(4) mixing the water-soluble ingredient solution in the step (2) and the fat-soluble ingredient solution in the step (3), and adding water to a constant volume to reach the final concentration of each component;
(5) homogenizing the solution with constant volume in the step (4) under high pressure;
(6) putting the material homogenized under high pressure in the step (5) into a glass container, and sealing;
(7) sterilizing the container filled with the materials in the step (6);
(8) and (5) cooling the sterilized product in the step (7) to obtain a finished product.
Preferably, the filtration in step (1) is performed by using a double-layer gauze with a pore size of 44 meshes.
Preferably, the high-pressure homogenizing pressure in the step (5) is 25-35 Mpa.
Preferably, the sterilization condition in the step (7) is that the temperature is 110-120 ℃, and the sterilization time is 10-15 min.
Advantageous effects
1. The premature infant formula liquid milk disclosed by the invention does not need to be prepared, is convenient to eat, has more uniform concentration and is more sanitary and safe compared with the traditional premature infant formula milk powder;
2. the weight ratio of the whey protein to the milk casein in the formula liquid milk for the premature infant is (5-6): 1, the kidney burden is reduced, and the absorption of premature infants is facilitated;
3. the skim milk is added into the liquid milk in the formula of the premature infant to replace the traditional skim milk powder, so that the skim milk more retains the original nutrient substances in the milk compared with the skim milk powder;
4. the skim milk is added into the liquid milk in the formula of the premature infant, and the fat is filled with the compound vegetable oil, so that the healthy proportion of saturated fatty acid and unsaturated fatty acid is ensured, the digestion and absorption are promoted, and the constipation of the premature infant is reduced;
5. the glucose polymer replaces part of lactose, is glycogen formed by connecting a plurality of monomeric glucose through glycosidic bonds, and can be converted into the monomeric glucose which is beneficial to the absorption of an organism through the glycogen;
6. the bifidobacterium animalis Bb-12 added into the liquid milk in the formula of the premature infant contains beta-galactosidase, and compared with bifidobacterium lactis HN-019 and bifidobacterium lactis Bi-07, the bifidobacterium animalis Bb-12 has higher survival rate, can better maintain intestinal lactose fermentation and promote lactose decomposition;
7. the liquid milk in the formula of the premature infant is added with taurine, so that the brain development, nerve conduction and visual function improvement of the premature infant are promoted;
8. the nucleotide is added into the formula liquid milk for premature infants to promote the growth of gastrointestinal tracts and improve the immunity;
9. lactoferrin is added into the formula liquid milk for the premature infant, so that the lactoferrin can regulate the running and storage of iron ions in a body, promote the proliferation of erythrocytes, promote the growth of bones, promote the proliferation and differentiation of epithelial cells of the small intestine and regulate the immune function of an organism;
10. according to the invention, an autoclave is used for in-bottle sterilization, the sterilization temperature is 110-120 ℃, the sterilization time is 10-15 min, and compared with an ultrahigh temperature instant sterilization method, the sterilization method has a better sterilization effect and is more suitable for feeding premature babies.
Detailed Description
The present invention will be further described with reference to the following specific examples, but the present invention is not limited to these examples.
The following examples relate to the following raw material information:
glucose polymers were purchased from Henan Nolan environmental technologies, Inc.;
bifidobacterium animalis was purchased from Sairantoze Biotech Ltd;
nucleotides were purchased from shanxi morning bioscience, ltd;
the compound vegetable oil is composed of soybean oil, corn oil, low erucic acid rapeseed oil, coconut oil and high oleic acid sunflower seed oil, and the mass ratio of the soybean oil, the corn oil, the low erucic acid rapeseed oil, the coconut oil and the high oleic acid sunflower seed oil is 5:37:23:19: 15. The compound vegetable oil used in the invention is purchased from Hebei Jiafeng vegetable oil Co Ltd;
the compound vitamin is composed of vitamin A, vitamin D, vitamin K, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, pantothenic acid, vitamin C, biotin and choline, and the mass ratio of the vitamin A, the vitamin D, the vitamin K, the vitamin E, the vitamin B1, the vitamin B2, the vitamin B6, the vitamin B12, the nicotinamide, the folic acid, the pantothenic acid, the vitamin C and the choline is 31:0.57:0.9:370:12.6:18.7:9.6:0.017:102.5:3.55:69:1630: 3429. The compound vitamin used in the invention is purchased from Guangzhou Shuowei food science and technology company;
the compound mineral substance is composed of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium, and the mass ratio of sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium is 3841:8213:5.71:859: 111:0.43:7430:4290:1.86:82130: 0.17. The compound mineral used in the invention is purchased from Guangzhou Shuowei food science and technology company;
example 1. preterm formula liquid milk.
The premature infant formula liquid milk described in this embodiment is prepared by taking the prepared liquid milk volume as a reference, and comprises raw milk with a mass concentration of 85g/L, skim milk with a mass concentration of 63g/L, compound vegetable oil with a mass concentration of 20g/L, whey protein powder with a mass concentration of 7g/L, desalted whey powder with a mass concentration of 95g/L, lactose with a mass concentration of 40g/L, glucose polymer with a mass concentration of 4g/L, compound vitamin with a mass concentration of 0.35g/L, compound mineral with a mass concentration of 0.35g/L, nucleotide with a mass concentration of 0.07g/L, taurine with a mass concentration of 0.45mg/L, lactoferrin with a mass concentration of 0.1g/L, bifidobacterium animalis with a mass concentration of 1400/L, and food additive with a mass concentration of 1 g/L.
The preparation method comprises the following specific steps:
(1) filtering raw milk by using double-layer gauze with the aperture of 44 meshes;
(2) mixing and dissolving the raw milk, the skim milk, the whey protein powder, the desalted whey powder, the lactose, the glucose polymer, the compound mineral, the nucleotide, the taurine, the lactoferrin, the bifidobacterium animalis Bb-12, the calcium carbonate and the calcium monohydrogen phosphate in the food additive and water after the filtration in the step (1) to obtain a water-soluble ingredient solution;
(3) adding the compound vitamins, soybean lecithin and mono-diglycerol fatty acid ester in the food additive into the compound vegetable oil, and mixing and dissolving the mixture to obtain a fat-soluble ingredient solution;
(4) mixing the water-soluble ingredient solution in the step (2) and the fat-soluble ingredient solution in the step (3), and fixing the volume to the final concentration of each component;
(5) homogenizing the solution with the constant volume in the step (4) at high pressure of 30 MPa;
(6) putting the material homogenized under high pressure in the step (5) into a glass container, and sealing;
(7) sterilizing the container filled with the materials in the step (6) at 115 ℃ for 13 min;
(8) and (5) cooling the sterilized product in the step (7) to obtain a finished product.
Example 2 preterm formula liquid milk.
The premature infant formula liquid milk described in this embodiment is prepared by taking the prepared liquid milk volume as a reference, wherein the raw milk mass concentration is 62g/L, the skim milk mass concentration is 65g/L, the compound vegetable oil mass concentration is 11.6g/L, the whey protein powder mass concentration is 7.5g/L, the desalted whey powder mass concentration is 91g/L, the lactose mass concentration is 58.5g/L, the glucose polymer mass concentration is 2.5g/L, the compound vitamin mass concentration is 0.5g/L, the compound mineral mass concentration is 0.2g/L, the nucleotide mass concentration is 0.09g/L, the taurine mass concentration is 0.4mg/L, the lactoferrin mass concentration is 0.13g/L, the bifidobacterium animalis Bb-12 mass concentration is 1000 g/L, and the food additive mass concentration is 1.02 g/L.
The preparation method comprises the following specific steps:
(1) filtering raw milk by using double-layer gauze with the aperture of 44 meshes;
(2) mixing and dissolving the raw milk, the skim milk, the whey protein powder, the desalted whey powder, the lactose, the glucose polymer, the compound mineral nucleotide, the taurine, the lactoferrin and the bifidobacterium animalis Bb-12 which are filtered in the step (1), the calcium carbonate and the calcium monohydrogen phosphate in the food additive and water to obtain a water-soluble ingredient solution;
(3) adding the compound vitamins, soybean lecithin and mono-diglycerol fatty acid ester in the food additive into the compound vegetable oil, and mixing and dissolving the mixture to obtain a fat-soluble ingredient solution;
(4) mixing the water-soluble ingredient solution in the step (2) and the fat-soluble ingredient solution in the step (3), and fixing the volume to the final concentration of each component;
(5) homogenizing the solution with constant volume in the step (4) at high pressure, wherein the pressure of the high-pressure homogenization is 35 Mpa;
(6) putting the material homogenized under high pressure in the step (5) into a glass container, and sealing;
(7) sterilizing the container filled with the materials in the step (6) at 120 ℃ for 15 min;
(8) and (5) cooling the sterilized product in the step (7) to obtain a finished product.
Example 3. preterm formula liquid milk.
The premature infant formula liquid milk described in this embodiment is prepared by taking the prepared liquid milk volume as a reference, wherein the raw milk mass concentration is 115g/L, the skim milk mass concentration is 62g/L, the compound vegetable oil mass concentration is 28.8g/L, the whey protein powder mass concentration is 6.5g/L, the desalted whey powder mass concentration is 100g/L, the lactose mass concentration is 22.5g/L, the glucose polymer mass concentration is 6.5g/L, the compound vitamin mass concentration is 0.25g/L, the compound mineral mass concentration is 0.5g/L, the nucleotide mass concentration is 0.05g/L, the taurine mass concentration is 0.5mg/L, the lactoferrin mass concentration is 0.05g/L, the bifidobacterium animalis Bb-12 mass concentration is 1800 g/L, and the food additive mass concentration is 0.95-1.02 g/L.
The preparation method comprises the following specific steps:
(1) filtering raw milk by using double-layer gauze with the aperture of 44 meshes;
(2) mixing and dissolving the raw milk, the skim milk, the whey protein powder, the desalted whey powder, the lactose, the glucose polymer, the compound mineral, the nucleotide, the taurine, the lactoferrin, the bifidobacterium animalis Bb-12, the calcium carbonate and the calcium monohydrogen phosphate in the food additive and water after the filtration in the step (1) to obtain a water-soluble ingredient solution;
(3) adding the compound vitamins, soybean lecithin and mono-diglycerol fatty acid ester in the food additive into the compound vegetable oil, and mixing and dissolving the mixture to obtain a fat-soluble ingredient solution;
(4) mixing the water-soluble ingredient solution in the step (2) and the fat-soluble ingredient solution in the step (3), and fixing the volume to the final concentration of each component;
(5) homogenizing the solution with constant volume in the step (4) at high pressure of 25 Mpa;
(6) putting the material homogenized under high pressure in the step (5) into a glass container, and sealing;
(7) sterilizing the container filled with the materials in the step (6) at the temperature of 110 ℃ for 10 min;
(8) and (5) cooling the sterilized product in the step (7) to obtain a finished product.
Comparative example 1 high oil preterm infant formula liquid milk.
Example 1 is repeated, and the difference from example 1 is that in the liquid milk raw material described in the comparative example, the weight concentration of the compounded vegetable oil is 30g/L based on the volume of the prepared liquid milk.
Comparative example 2 low oil preterm formula liquid milk.
Example 1 is repeated, and the difference from example 1 is that in the liquid milk raw material described in the comparative example, the weight concentration of the compounded vegetable oil is 10g/L based on the volume of the prepared liquid milk.
Comparative example 3 full fat preterm formula liquid milk.
According to the formula liquid milk for the premature infant, based on the volume of the prepared liquid milk, each 1000L of the formula liquid milk contains 134.02kg of fresh raw milk, 7.3kg of whey protein powder, 40.58kg of desalted whey powder, 52.8kg of lactose, 6.5kg of glucose polymer, 0.27kg of compound vitamin, 0.22kg of compound mineral, 0.08kg of nucleotide and 0.12kg of lactoferrin.
The specific preparation method is the same as that of example 1.
Comparative example 4. preterm formula liquid milk fortified with no taurine, nucleotides, lactoferrin.
The formula liquid milk for the premature infant described in this embodiment contains, based on the volume of the prepared liquid milk, 95.27kg of fresh raw milk, 50.26kg of skim milk, 20.2kg of compound vegetable oil, 7kg of whey protein powder, 73.6kg of desalted whey powder, 43.5kg of glucose polymer, 0.27kg of compound vitamin, and 0.22kg of compound mineral substance per 1000L.
The specific preparation method is the same as that of example 1.
To demonstrate the effects that can be obtained by the present invention, the following experiments were carried out:
sensory evaluation and mouse experiments were carried out using the preterm formula liquid milk prepared in example 1, comparative example 1 and comparative example 2 to demonstrate that the formula liquid milk suitable for preterm infants is good in homogeneity and can promote digestive absorption and development of brain nerves.
1. Sensory evaluation: selecting 10 professionals with dairy product expertise and receiving sensory evaluation training for sensory evaluation.
The grading standard comprises taste, smell, tissue state and color, and the proportion of the taste, the smell, the tissue state and the color is respectively 60, 30 and 10 for sensory grading.
TABLE 1 sensory evaluation Table
Single item score: when calculating the score, one of the highest score and the lowest score should be removed from the total singles scores. The calculation is carried out according to the following formula, and the result is an integer.
Single score is the sum of the remaining single scores/(assessor number-2)
Total points are as follows: when calculating the score, one highest score and one lowest score should be removed from the total score. Calculated according to the following formula. The result is an integer.
Total score is the sum of the remaining total scores/(number of assessors-2)
The following table is the sensory evaluation results:
TABLE 2 sensory evaluation Total score of the examples
| Experimental group | Total score |
| Example 1 (Compound vegetable oil medium dose) | 88 |
| Comparative example 1 (high dose of compounded vegetable oil) | 98 |
| Comparative example 2 (Low dose of compounded vegetable oil) | 95 |
According to table 2, it can be found that when the compound vegetable oil is added in the medium-dose group, the sensory evaluation score of the preterm formula liquid milk is up to 98 points, and the color, the taste and the tissue state of the product are more suitable for consumers and preterm infants compared with the high-dose group and the low-dose group.
2. Mouse experiment
(1) Experimental Material
Experimental materials: selecting SPF-grade healthy Kunming mice with the weight of 20 +/-0.5 g, using male and female simultaneously, adapting for 3 days under natural illumination at the room temperature of 21 +/-1 ℃ and the indoor relative humidity RH (32% +/-2%) in an experimental environment, feeding the prepared feed during the adaptation period, freely feeding water, and stopping feeding in the morning on the 4 th day.
(2) Experimental methods and procedures
150 mice, male and female halves, were randomly divided into 5 groups. The following formulated liquid milks, example 1, comparative example 2, comparative example 3, and comparative example 4 were fed, respectively.
Quantitatively filling 0.5mL of formula liquid milk into each mouse, slaughtering three animals in each group at 0.5h, 1h, 2h and 4h, rapidly opening abdominal cavity, taking out stomach and duodenum, and storing small intestine in ice box for determining fat digestibility, glucose polymer digestibility and protein digestibility.
1) Fat digestibility determination
Flushing the digestive tract with normal saline, collecting gastric juice and intestinal juice in normal saline, and measuring the fat content in each sample by an acid hydrolysis method to obtain the total fat content of the gavage emulsion as the digestibility.
Fat digestibility (%) - (total fat content in sample-gastrointestinal fat content)/total fat content in sample x 100%
TABLE 3 Effect of preterm formula liquid milk on fat digestibility in mice
As can be seen from table 3, the fat digestibility of the preterm formula liquid milk with the added compounded vegetable oil was higher in the mouse digestion test compared to the full fat preterm formula liquid milk. The lowest fat digestibility of the liquid milk of the full fat preterm formula fully indicates that the liquid milk of the full fat preterm formula is not suitable for the preterm. The preterm formula in the high dose group had a higher digestibility during the early stages of digestion and the fat digestibility increased well with time. In contrast, however, the total digestibility of fat was not as good as in the medium dose addition group. Medium dose addition group the initial digestibility of the preterm formula liquid milk was not as good as in the high dose group, but over time the digestibility of the preterm formula liquid milk was progressively higher than in the high dose group. The digestibility of the preterm formula liquid milk in the medium dose group is therefore better. The effects obtained in example 2 and example 3 are similar to those of example 1.
2) Mouse T cell subsets and immune factor assay
120 mice, half male and half female, were randomly divided into 5 groups. The following formulated liquid milks, example 1, comparative example 2, comparative example 3, and comparative example 4 were fed, respectively.
After the experiment is started, 3 mice are randomly taken from each group on the 0 th day and the 28 th day, after ether anesthesia, the heart is subjected to blood sampling, EDTA (ethylene diamine tetraacetic acid) anticoagulation, 10 mu L of peripheral blood is sucked into an EP (EP) tube, 1 mu L of CD3-FITC, CD4-PE and CD8a-Per CP monoclonal antibodies are respectively added to the peripheral blood and dyed in a dark place for 30min, 2ml of erythrocyte lysate with the ratio of 1:10 is added to each sample, the mixture is uniformly mixed, and the mixture is stood at the room temperature for 10min and then centrifuged at 3000r/min for 5 min. The supernatant was carefully discarded, 2ml of PBS buffer pH 7.4 was added, the mixture was washed 2 times, the supernatant was discarded, 400. mu.L of PBS buffer was added and mixed, and the number of CD3+ T, CD4+ T, CD8+ T cells was measured on a flow cytometer within 1 hour.
TABLE 4 Effect of preterm formula liquid milk on mouse T cell subpopulations
As can be seen from table 4, in example 1, comparative examples 1,2 and 3, T lymphocyte CD3+ showed significant difference (p <0.05), T lymphocyte CD4+ also showed significant difference (p <0.05) and T lymphocyte CD8+ showed no significant difference although it was increased compared with comparative example 4. T cells can participate in cellular immunity, so that the addition of nucleotides and lactoferrin is shown to improve the proliferation and growth of the T cells and improve the cellular immunity. The effects obtained in example 2 and example 3 are similar to those of example 1.
3) Diving platform experiment
40 male Kunming mice were randomly divided into 5 groups. The following formulated liquid milks, example 1, comparative example 2, comparative example 3, and comparative example 4 were fed, respectively.
The study and memory ability of each group of mice is tested by adopting a diving platform method, and the test is carried out in a quiet environment. The mouse diving tower instrument is divided into 2 rooms by a black plastic plate, a copper grid capable of being electrified is paved on the bottom surface of the mouse diving tower instrument, and a rubber platform with the length, width and height of 5cm is arranged in each room and is used as a safety area for avoiding electric shock of animals. During the experiment, the animal is firstly put into the reaction box to adapt for 3min, then the power is immediately switched on, the animal is shocked by electricity, and the escape reaction is that the animal jumps to the rubber table. At the moment, the electric stimulation is turned off, the mouse jumps to the copper grid for multiple times due to the fact that the mouse feels unsafe, when the four limbs of the mouse fall on the copper grid, the electric stimulation is turned on, the mouse jumps back to the platform quickly after receiving the electric shock, and the training is carried out for 5 min. After 24 hours, under the condition that a copper grid at the bottom is electrified, the mouse is directly and lightly placed on the platform, the time from the time when the mouse is placed on the rubber table to the time when the mouse jumps down for the first time is recorded, the latency period (LT) is called, the mouse can jump on the rubber table in an evasive way after being shocked, the number (n) of times when the mouse jumps down within 5min is recorded, and the LT and n are jointly used as the learning and memory achievement of the mouse.
Table 5 achievement of kunming mice in the diving platform experiment (n ═ 8)
| Group number | Incubation period | Number of times of jumping from one platform to another |
| Example 1 | 172.54±116.57 | 1.22±0.93 |
| Comparative example 1 | 170.37±143.21 | 1.41±0.71 |
| Comparative example 2 | 171.24±119.74 | 1.31±0.99 |
| Comparative example 3 | 171.78±121.14 | 1.35±0.77 |
| Comparative example 4 | 184.26±118.64 | 0.76±0.92 |
As shown in Table 5, the latency period and the number of jumping from the platform were not significantly different (p >0.01) in the case of example 1 and the cases of comparative examples 1,2 and 3 compared with the case of comparative example 4, but it was found that the cases of example 1 and the cases of comparative examples 1,2 and 3 compared with the case of comparative example 4 were increased, indicating that taurine promotes the development of the cerebral nerves and improves the learning and memory ability of the mice.
The effects obtained in example 2 and example 3 are similar to those of example 1.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911044599.8A CN112741154A (en) | 2019-10-30 | 2019-10-30 | Formula liquid milk for premature infants and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911044599.8A CN112741154A (en) | 2019-10-30 | 2019-10-30 | Formula liquid milk for premature infants and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112741154A true CN112741154A (en) | 2021-05-04 |
Family
ID=75641685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911044599.8A Pending CN112741154A (en) | 2019-10-30 | 2019-10-30 | Formula liquid milk for premature infants and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112741154A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190733A1 (en) * | 2001-01-25 | 2003-10-09 | Pradip Mukerji | Desaturase genes and uses thereof |
| KR20060118703A (en) * | 2005-05-17 | 2006-11-24 | 매일유업주식회사 | Method for preparing breast milk fortifying infant and preserving mother milk fortifying |
| CN106035674A (en) * | 2016-06-24 | 2016-10-26 | 吉林大学 | Prebiotics-added formula milk powder suitable for premature infants and infants with low birth weight and preparation method thereof |
| CN106615147A (en) * | 2016-09-30 | 2017-05-10 | 建水县鸿辉种养殖产业有限公司 | Baby formula milk powder containing desalted sheep whey powder and production method of baby formula milk powder |
| CN107927198A (en) * | 2017-12-19 | 2018-04-20 | 光明乳业股份有限公司 | One kind drinks milk powder and preparation method thereof for premature |
| CN109793044A (en) * | 2019-03-21 | 2019-05-24 | 贝因美（杭州）食品研究院有限公司 | A kind of formula milk and preparation method thereof eaten suitable for premature labor/low birth weight baby |
| CN112640957A (en) * | 2020-12-18 | 2021-04-13 | 北京三元食品股份有限公司 | Formula milk powder for premature infants and preparation method thereof |
| CN112931628A (en) * | 2021-03-26 | 2021-06-11 | 东北农业大学 | Liposome simulating breast milk lipid structure, formula powder for premature infant and preparation method |
-
2019
- 2019-10-30 CN CN201911044599.8A patent/CN112741154A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190733A1 (en) * | 2001-01-25 | 2003-10-09 | Pradip Mukerji | Desaturase genes and uses thereof |
| KR20060118703A (en) * | 2005-05-17 | 2006-11-24 | 매일유업주식회사 | Method for preparing breast milk fortifying infant and preserving mother milk fortifying |
| CN106035674A (en) * | 2016-06-24 | 2016-10-26 | 吉林大学 | Prebiotics-added formula milk powder suitable for premature infants and infants with low birth weight and preparation method thereof |
| CN106615147A (en) * | 2016-09-30 | 2017-05-10 | 建水县鸿辉种养殖产业有限公司 | Baby formula milk powder containing desalted sheep whey powder and production method of baby formula milk powder |
| CN107927198A (en) * | 2017-12-19 | 2018-04-20 | 光明乳业股份有限公司 | One kind drinks milk powder and preparation method thereof for premature |
| CN109793044A (en) * | 2019-03-21 | 2019-05-24 | 贝因美（杭州）食品研究院有限公司 | A kind of formula milk and preparation method thereof eaten suitable for premature labor/low birth weight baby |
| CN112640957A (en) * | 2020-12-18 | 2021-04-13 | 北京三元食品股份有限公司 | Formula milk powder for premature infants and preparation method thereof |
| CN112931628A (en) * | 2021-03-26 | 2021-06-11 | 东北农业大学 | Liposome simulating breast milk lipid structure, formula powder for premature infant and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 洪滨等: "仿早产儿母乳脂肪配方奶粉及其消化率的评价", 《食品科技》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5864676B2 (en) | Composition for preventing or treating anemia | |
| RU2600877C2 (en) | Fermented infant formula | |
| CN107549456B (en) | A compound probiotic agent for improving goose intestinal function and preparation method thereof | |
| CN104206539A (en) | Probiotic-containing infant milk powder | |
| CN104855721A (en) | Lactating sow compound feed capable of improving piglet sow production performance | |
| CN106418544A (en) | Protein and probiotic composite food with weight losing effect | |
| CN107549612B (en) | Nutritional formula rice flour capable of improving immunity of 6-12 month-old infants | |
| CN103181496A (en) | Milk for piglets | |
| CN112075504A (en) | Infant formula milk powder for enhancing immunity | |
| CN109221675A (en) | A kind of feed additive for weaning piglet and preparation method thereof | |
| CN112167360A (en) | Hypoallergenic infant formula goat milk powder | |
| CN114145346A (en) | Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder | |
| CN111919889A (en) | Mother-emulsified infant formula goat milk powder capable of improving immunity and preparation method thereof | |
| CN110692741A (en) | Formula milk powder for promoting bone growth and preparation method thereof | |
| EA011075B1 (en) | Dry powdered milk formula | |
| Kariyawasam et al. | Comparative Analysis of Breastfeeding and Infant Formulas: Short‐and Long‐Term Impacts on Infant Nutrition and Health | |
| CN102669474B (en) | High-efficiency piglet feed and its preparation method | |
| CN107629981B (en) | A compound probiotic agent for improving intestinal function of chicks and preparation method thereof | |
| CN119138609B (en) | The use of human milk oligosaccharides to improve the intestinal flora of mothers and infants | |
| CN112841310A (en) | Newborn formula liquid milk and preparation method thereof | |
| CN107927198A (en) | One kind drinks milk powder and preparation method thereof for premature | |
| CN112741154A (en) | Formula liquid milk for premature infants and preparation method thereof | |
| US20210037854A1 (en) | Eggs rich in nutrients of alpha-linolenic acid and dha, breeding method of laying hens, and feed additive | |
| CN120391525A (en) | A milk powder composition containing human milk oligosaccharides that is easy to digest and absorb and its application | |
| CN111201026A (en) | Fermented milk and polysaccharides having cancer cachexia inhibitory action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |